Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.56 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14418828 | 0.92 | GSK3B (0.57) | GSK3BNAMPTCYP2C9CYP3A4CYP2D6 | |
| SCHEMBL14307166 | 0.91 | GSK3B (0.56) | GSK3BNAMPTCYP2C9CYP3A4CYP2D6 | |
| SCHEMBL14581275 | 0.91 | GSK3B (0.70) | GSK3BCCNE1CDK2 | |
| SCHEMBL13304919 | 0.87 | GSK3B (0.62) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL13289097 | 0.86 | GSK3B (0.59) | GSK3BNAMPTCHEK1LMNACCNE1 | |
| SCHEMBL13120527 | 0.86 | GSK3B (0.74) | GSK3BCCNE1CDK2 | |
| SCHEMBL14613487 | 0.85 | GSK3B (0.56) | GSK3BCHEK1CDK2 | |
| SCHEMBL13120506 | 0.85 | GSK3B (0.71) | GSK3BCYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13120561 | 0.85 | GSK3B (0.70) | GSK3BCCNE1CDK2 | |
| SCHEMBL13288870 | 0.85 | GSK3B (0.56) | GSK3BNAMPTCHEK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | GSK3B 749/4885NAMPT 677/4885CYP2C9 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.